Cyclacel Pharmaceuticals, Inc. Provides Update on Meeting With FDA to Discuss Pivotal Study Design for Sapacitabine

BERKELEY HEIGHTS, N.J., Dec. 15, 2009 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (“Cyclacel” or the “Company”) announced today that the Company recently held a Type A meeting with the U.S. Food and Drug Administration (FDA) to discuss a randomized Phase 3 study design for Cyclacel’s oral sapacitabine capsules in acute myeloid leukemia (AML) and separately in myelodysplastic syndromes (MDS).